Nirosha D Perera1, Aaron S Mansfield2. 1. Department of Internal Medicine, Mayo Clinic, Rochester, MN, 55905, USA. 2. Division of Medical Oncology, Mayo Clinic, 200 First Street Southwest, Rochester, MN, 55905, USA. mansfield.aaron@mayo.edu.
Abstract
PURPOSE OF REVIEW: For patients with malignant pleural mesothelioma, prognosis is poor with extremely low 5-year survival rates and limited therapeutic options. Here, we review the current treatment landscape for mesothelioma and highlight promising future therapeutic directions. RECENT FINDINGS: Evolving frontline therapeutic options for mesothelioma include VEGF inhibition in combination with chemotherapy and dual immune checkpoint inhibition, with synergisms between the therapies and response prediction via biomarkers also being explored. Evolving experimental treatments for mesothelioma include PARP and ALK inhibitors, dendritic and CAR T-cell therapies, anti-mesothelin vaccines, and oncolytic viral therapies, representing timely advances in the field. The therapeutic landscape for malignant pleural mesothelioma is evolving and preferred treatment in the frontline and later settings will likely evolve with it. However, this does not preclude the evidence for including multi-modal therapies spanning angiogenesis and immune checkpoint inhibitors, and biomarker utilization, in current clinical trials and management.
PURPOSE OF REVIEW: For patients with malignant pleural mesothelioma, prognosis is poor with extremely low 5-year survival rates and limited therapeutic options. Here, we review the current treatment landscape for mesothelioma and highlight promising future therapeutic directions. RECENT FINDINGS: Evolving frontline therapeutic options for mesothelioma include VEGF inhibition in combination with chemotherapy and dual immune checkpoint inhibition, with synergisms between the therapies and response prediction via biomarkers also being explored. Evolving experimental treatments for mesothelioma include PARP and ALK inhibitors, dendritic and CAR T-cell therapies, anti-mesothelin vaccines, and oncolytic viral therapies, representing timely advances in the field. The therapeutic landscape for malignant pleural mesothelioma is evolving and preferred treatment in the frontline and later settings will likely evolve with it. However, this does not preclude the evidence for including multi-modal therapies spanning angiogenesis and immune checkpoint inhibitors, and biomarker utilization, in current clinical trials and management.
Authors: Nico van Zandwijk; Christopher Clarke; Douglas Henderson; A William Musk; Kwun Fong; Anna Nowak; Robert Loneragan; Brian McCaughan; Michael Boyer; Malcolm Feigen; David Currow; Penelope Schofield; Beth Ivimey Nick Pavlakis; Jocelyn McLean; Henry Marshall; Steven Leong; Victoria Keena; Andrew Penman Journal: J Thorac Dis Date: 2013-12 Impact factor: 2.895
Authors: Aaron Scott Mansfield; Anja C Roden; Tobias Peikert; Yuri M Sheinin; Susan M Harrington; Christopher J Krco; Haidong Dong; Eugene D Kwon Journal: J Thorac Oncol Date: 2014-07 Impact factor: 15.609
Authors: Dean A Fennell; Amit Parmar; Jonathan Shamash; Marie T Evans; Michael T Sheaff; Richard Sylvester; Kevin Dhaliwal; Nicole Gower; Jeremy Steele; Robin Rudd Journal: J Clin Oncol Date: 2005-01-01 Impact factor: 44.544
Authors: Edward J A Harris; Steven Kao; Brian McCaughan; Takashi Nakano; Nobuyuki Kondo; Rebecca Hyland; Anna K Nowak; Nicholas H de Klerk; Fraser J H Brims Journal: J Thorac Oncol Date: 2018-10-24 Impact factor: 15.609
Authors: L E Dalton; H J Clarke; J Knight; M H Lawson; J Wason; D A Lomas; W J Howat; R C Rintoul; D M Rassl; S J Marciniak Journal: Br J Cancer Date: 2013-02-14 Impact factor: 7.640